{"id":"https://openalex.org/W4367624557","doi":"https://doi.org/10.1158/2643-3249.aml23-a35","title":"Abstract A35: Overcoming Venetoclax Resistance in Acute Myeloid Leukemia (AML) via the Novel Imipridone ONC213","display_name":"Abstract A35: Overcoming Venetoclax Resistance in Acute Myeloid Leukemia (AML) via the Novel Imipridone ONC213","publication_year":2023,"publication_date":"2023-05-01","ids":{"openalex":"https://openalex.org/W4367624557","doi":"https://doi.org/10.1158/2643-3249.aml23-a35"},"language":"en","primary_location":{"id":"doi:10.1158/2643-3249.aml23-a35","doi":"https://doi.org/10.1158/2643-3249.aml23-a35","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/2643-3249.aml23-a35","pdf_url":null,"source":{"id":"https://openalex.org/S4210239195","display_name":"Blood Cancer Discovery","issn_l":"2643-3230","issn":["2643-3230","2643-3249"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-20","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Discovery","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040504042","display_name":"Jenna L. Carter","orcid":"https://orcid.org/0000-0001-6933-2044","observed_orcids":["https://orcid.org/0000-0001-6933-2044"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jenn L. Carter","raw_affiliation_strings":["1Wayne State University, Detroit, MI,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Wayne State University, Detroit, MI,","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010440853","display_name":"Yongwei Su","orcid":"https://orcid.org/0009-0008-3354-1811","observed_orcids":["https://orcid.org/0009-0008-3354-1811"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yongwei Su","raw_affiliation_strings":["2Wayne State University, Detroit, MI,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Wayne State University, Detroit, MI,","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061036650","display_name":"Holly J. Edwards","orcid":"https://orcid.org/0009-0009-5693-8122","observed_orcids":["https://orcid.org/0009-0009-5693-8122"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holly Edwards","raw_affiliation_strings":["1Wayne State University, Detroit, MI,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Wayne State University, Detroit, MI,","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084102458","display_name":"Lisa Polin","orcid":"https://orcid.org/0000-0002-9189-055X","observed_orcids":["https://orcid.org/0000-0002-9189-055X"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Polin","raw_affiliation_strings":["1Wayne State University, Detroit, MI,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Wayne State University, Detroit, MI,","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008547275","display_name":"Joshua E. Allen","orcid":"https://orcid.org/0000-0002-6835-1128","observed_orcids":["https://orcid.org/0000-0002-6835-1128"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua E. Allen","raw_affiliation_strings":["1Wayne State University, Detroit, MI,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Wayne State University, Detroit, MI,","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056800304","display_name":"Varun V. Prabhu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119210","display_name":"Chimerix (United States)","ror":"https://ror.org/02jsvy381","country_code":"US","type":"company","lineage":["https://openalex.org/I4210119210"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Varun V. Prabhu","raw_affiliation_strings":["3Chimerix, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Chimerix, Durham, NC","institution_ids":["https://openalex.org/I4210119210"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027520603","display_name":"Jay Yang","orcid":"https://orcid.org/0000-0003-0790-7951","observed_orcids":["https://orcid.org/0000-0003-0790-7951"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jay Yang","raw_affiliation_strings":["1Wayne State University, Detroit, MI,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Wayne State University, Detroit, MI,","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083955203","display_name":"Maik Huettermann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maik Huettermann","raw_affiliation_strings":["1Wayne State University, Detroit, MI,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Wayne State University, Detroit, MI,","institution_ids":["https://openalex.org/I185443292"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100638112","display_name":"Yubin Ge","orcid":"https://orcid.org/0000-0002-8748-716X","observed_orcids":["https://orcid.org/0000-0002-8748-716X"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yubin Ge","raw_affiliation_strings":["1Wayne State University, Detroit, MI,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Wayne State University, Detroit, MI,","institution_ids":["https://openalex.org/I185443292"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"4","issue":"3_Supplement","first_page":"A35","last_page":"A35"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12582","display_name":"Flavonoids in Medical Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venetoclax-resistance","display_name":"venetoclax resistance","score":0.9459999799728394},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9940000176429749},{"id":"https://openalex.org/keywords/imipridone","display_name":"imipridone","score":0.9950000047683716},{"id":"https://openalex.org/keywords/mcl-1","display_name":"Mcl-1","score":0.9120000004768372},{"id":"https://openalex.org/keywords/mitochondria","display_name":"mitochondria","score":0.6679999828338623},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5429999828338623},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.7570000290870667},{"id":"https://openalex.org/keywords/synergistic-drug-combination","display_name":"synergistic drug combination","score":0.5210000276565552},{"id":"https://openalex.org/keywords/mouse-xenograft-model","display_name":"xenograft mouse model","score":0.9210000038146973},{"id":"https://openalex.org/keywords/older-adults","display_name":"older adults","score":0.45500001311302185},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.6669999957084656},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.7129999995231628}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.84148770570755},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.8395404815673828},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.8004046678543091},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7834100723266602},{"id":"https://openalex.org/C9583187","wikidata":"https://www.wikidata.org/wiki/Q7919510","display_name":"Ven","level":2,"score":0.7595491409301758},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.6271259784698486},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5865221619606018},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5407881736755371},{"id":"https://openalex.org/C2776012956","wikidata":"https://www.wikidata.org/wiki/Q17125294","display_name":"Hypomethylating agent","level":5,"score":0.5160796046257019},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.502612829208374},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5009632110595703},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.46835556626319885},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4548429250717163},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3450787663459778},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.16964998841285706},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.123650461435318},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.09246411919593811},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/2643-3249.aml23-a35","doi":"https://doi.org/10.1158/2643-3249.aml23-a35","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/2643-3249.aml23-a35","pdf_url":null,"source":{"id":"https://openalex.org/S4210239195","display_name":"Blood Cancer Discovery","issn_l":"2643-3230","issn":["2643-3230","2643-3249"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-20","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood Cancer Discovery","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W6902521548","https://openalex.org/W3211472174","https://openalex.org/W4416842582","https://openalex.org/W7217718971","https://openalex.org/W7148912436","https://openalex.org/W7204496370","https://openalex.org/W2980235102","https://openalex.org/W4410809249","https://openalex.org/W2343244371","https://openalex.org/W3213615512"],"abstract_inverted_index":{"Abstract":[0],"Older":[1],"adults":[2],"make":[3],"up":[4],"most":[5],"of":[6,67,76,107,127,177,243,285,339,360,393,427,495],"the":[7,65,111,124,337,432,488,496],"AML":[8,45,164,178,203,220,275,300,377],"patient":[9,169,208],"population":[10],"and":[11,63,69,81,110,145,167,174,181,196,206,228,263,268,273,279,287,298,304,322,336,341,349,365,374,409,429,445,503],"have":[12,135,154],"an":[13,294],"especially":[14],"dismal":[15],"prognosis":[16],"due":[17],"to":[18,59,97,130,187,214,261,314,334,384,390,411,443,450],"limited":[19],"therapeutic":[20,91],"options.":[21],"The":[22,216],"Bcl-2":[23],"inhibitor,":[24],"venetoclax":[25],"(VEN),":[26],"was":[27,88,182],"approved":[28],"for":[29,54,78,84,93],"use":[30],"in":[31,44,101,193,201,230,233,249,308,346,366,376,454,482],"combination":[32,66,217,338,356,367,400],"with":[33,368,381,387],"low-dose":[34],"cytarabine":[35],"or":[36,42,52,386],"a":[37,73,89,102,151,184,234,355,447],"hypomethylating":[38],"agent":[39,186],"[azacitidine":[40],"(AZA)":[41],"decitabine]":[43],"patients":[46,80],"who":[47],"are":[48,198],"\u226575":[49],"years":[50],"old":[51],"ineligible":[53],"intensive":[55],"chemotherapy":[56],"(IC).":[57],"Due":[58],"superior":[60],"survival":[61,105,114,242],"data":[62],"tolerability,":[64],"VEN":[68,137,189,197,262,267,286,335,342,369,385,413,419,438,444],"AZA":[70,269,288,440],"has":[71,158],"become":[72],"new":[74,128,448],"standard":[75],"care":[77],"older":[79],"those":[82,211,380],"unfit":[83],"IC.":[85],"Though":[86],"this":[87,98],"promising":[90,185],"option":[92],"these":[94],"patients,":[95],"resistance":[96,138,260,383,389,420,453],"therapy":[99],"results":[100,403],"1-year":[103],"overall":[104,113],"rate":[106],"only":[108],"30-40%":[109],"median":[112],"following":[115],"treatment":[116],"failure":[117],"is":[118,343],"less":[119],"than":[120],"three":[121],"months,":[122],"highlighting":[123],"urgent":[125],"need":[126],"therapies":[129],"address":[131],"this.":[132],"Previous":[133],"studies":[134,148],"found":[136,155],"can":[139,330,395,421],"be":[140,422],"overcome":[141,188,258,412],"by":[142,224,281,354],"targeting":[143,426],"mitochondria":[144,176,428],"Mcl-1.":[146],"Our":[147],"on":[149],"ONC213,":[150],"novel":[152,433],"imipridone,":[153,434],"that":[156,405,418],"it":[157],"potent":[159],"antileukemic":[160],"activity":[161],"against":[162],"both":[163,202,347],"cell":[165,204,235],"lines":[166,205],"primary":[168,207],"samples.":[170],"It":[171],"reduces":[172],"Mcl-1":[173,375,394,410,430],"targets":[175,219],"cells":[179,222,276,301,316,333,351,398,442],"\u2013":[180],"thus":[183],"resistance.":[190,414],"When":[191],"used":[192],"combination,":[194],"ONC213":[195,256,329,340,363,406,436,491],"highly":[199,344],"synergistic":[200,345],"samples,":[209],"including":[210,379],"intrinsically":[212],"resistant":[213,271,332,441],"VEN.":[215],"also":[218],"progenitor":[221],"determined":[223],"colony":[225],"formation":[226],"assays":[227],"shows":[229],"vivo":[231],"efficacy":[232],"line":[236],"derived":[237],"xenograft":[238],"mouse":[239],"model":[240],"(median":[241],"57":[244],"days":[245,248],"vs":[246,319,325],"37":[247],"control":[250],"mice,":[251],"p=0.002).":[252],"To":[253],"determine":[254],"if":[255],"could":[257],"acquired":[259,388],"AZA,":[264],"we":[265,416],"developed":[266],"double":[270],"ML-2":[272],"MV4-11":[274],"(designated":[277],"ML-2/VEN+AZA-R":[278,297,348],"MV4-11/VEN+AZA-R)":[280],"stepwise":[282],"increasing":[283],"concentrations":[284],"at":[289],"1:3":[290],"fixed":[291],"ratio":[292],"over":[293],"extended":[295],"period.":[296],"MV4-11/VEN+AZA-R":[299,350],"demonstrate":[302,417],"437-":[303],"1156-fold,":[305],"respectively,":[306],"increase":[307],"VEN+AZA":[309,452],"(1:3":[310],"ratio)":[311],"IC50":[312],"compared":[313],"parental":[315],"(5,285.3":[317],"nM":[318,321,324],"12.1":[320],"6,704.3":[323],"5.8":[326],"nM,":[327],"respectively).":[328],"resensitize":[331],"as":[352],"evident":[353],"index":[357],"(CI)":[358],"value":[359],"<":[361],"0.05.":[362],"alone":[364],"suppress":[370],"oxidative":[371],"phosphorylation":[372],"(OXPHOS)":[373],"cells,":[378],"inherent":[382],"VEN+AZA.":[391],"Overexpression":[392],"partially":[396],"rescue":[397],"from":[399],"therapy.":[401],"These":[402],"suggest":[404],"suppresses":[407],"OXPHOS":[408],"Here":[415],"addressed":[423],"through":[424],"dual":[425],"using":[431],"ONC213.":[435],"resensitizes":[437],"+":[439],"offers":[446],"approach":[449],"combat":[451],"AML.":[455],"Citation":[456],"Format:":[457],"Jenn":[458],"L.":[459],"Carter,":[460],"Yongwei":[461],"Su,":[462],"Holly":[463],"Edwards,":[464],"Lisa":[465],"Polin,":[466],"Joshua":[467],"E.":[468],"Allen,":[469],"Varun":[470],"V.":[471],"Prabhu,":[472],"Jay":[473],"Yang,":[474],"Maik":[475],"Huettermann,":[476],"Yubin":[477],"Ge.":[478],"Overcoming":[479],"Venetoclax":[480],"Resistance":[481],"Acute":[483,500],"Myeloid":[484,501],"Leukemia":[485,502],"(AML)":[486],"via":[487],"Novel":[489],"Imipridone":[490],"[abstract].":[492],"In:":[493],"Proceedings":[494],"AACR":[497],"Special":[498],"Conference:":[499],"Myelodysplastic":[504],"Syndrome;":[505],"2023":[506],"Jan":[507],"23-25;":[508],"Austin,":[509],"TX.":[510],"Philadelphia":[511],"(PA):":[512],"AACR;":[513],"Blood":[514],"Cancer":[515],"Discov":[516],"2023;4(3_Suppl):Abstract":[517],"nr":[518],"A35.":[519]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-05-02T00:00:00"}